Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bioabsorbable Therapeutics Inc.

This article was originally published in Start Up

Executive Summary

Bioabsorbable Therapeutics, a start-up built around technology developed at Rutgers University, expects to begin conducting clinical trials on its bioabsorbable stent. The company, which is constructing the stents with polymers that contain non-sterioidal anti-inflammatories, is targeting the coronary market.

You may also be interested in...



ACC Wrap-Up: Device Companies Win a Few, Lose a Few

Several interesting studies came out of this year's joint meeting of the American College of Cardiology and Society for Cardiovascular Angiography and Interventions. These studies--many of them about drug-eluting stents--will impact device manufacturers in both positive and negative ways.

Stent Recap: Turmoil in 2007--What's Ahead for Interventional Cardiology?

Although safety concerns about drug-eluting stents have been mitigated somewhat by recent reports of more positive clinical data, there is lingering unease and confusion in the cardiology community about when, how, and in whom to use these devices. There is also a growing wave of healthy skepticism about the way stent trials are designed and conducted, and whether evidence- based medicine is well served by the current process.

Arterial Remodeling Technologies

Paris-based Arterial Remodeling Technologies is developing a bioabsorbable stent that may not require the use of anti-inflammatories.

Related Content

Topics

Related Companies

Related Deals

Latest News
UsernamePublicRestriction

Register

MT037461

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel